Last updated: 14:46
No Notes Added Yet
Mono Pharmacare Ltd. is a pharmaceutical company engaged in the manufacturing, marketing, and distribution of a range of pharmaceutical products. The company focuses on producing generic medicines, including tablets, capsules, syrups, and other dosage forms, catering to therapeutic areas such as antibiotics, pain relief, cardiovascular, and general healthcare. Its products are distributed through a network of stockists, distributors, and medical professionals targeting hospitals, clinics, and retail pharmacies. Mono Pharmacare Ltd. operates in...Read More
Mono Pharmacare Ltd. is a pharmaceutical company engaged in the manufacturing, marketing, and distribution of a range of pharmaceutical products. The company focuses on producing generic medicines, including tablets, capsules, syrups, and other dosage forms, catering to therapeutic areas such as antibiotics, pain relief, cardiovascular, and general healthcare. Its products are distributed through a network of stockists, distributors, and medical professionals targeting hospitals, clinics, and retail pharmacies. Mono Pharmacare Ltd. operates in a highly regulated industry and emphasizes quality compliance, cost-effective production, and expanding its product portfolio to meet evolving healthcare needs. The company’s performance depends on factors like regulatory approvals, competition from established pharma companies, raw material costs, and market demand. As a small to mid-sized pharmaceutical player, Mono Pharmacare Ltd. offers growth potential driven by increasing healthcare access, generic drug demand, and opportunities in domestic and export markets, while also facing challenges related to pricing pressures and stringent regulatory standards ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹23 Cr.
Stock P/E 7.5
P/B 0.8
Current Price ₹13.3
Book Value ₹ 17.7
Face Value 10
52W High ₹28.3
Dividend Yield 0%
52W Low ₹ 9.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 27 | 122 | 168 | |
| Other Income | 0 | 0 | 1 | |
| Total Income | 27 | 122 | 169 | |
| Total Expenditure | 25 | 116 | 161 | |
| Operating Profit | 2 | 6 | 9 | |
| Interest | 1 | 3 | 4 | |
| Depreciation | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 3 | 4 | |
| Provision for Tax | 0 | 1 | 1 | |
| Profit After Tax | 1 | 2 | 3 | |
| Adjustments | -0 | -0 | -0 | |
| Profit After Adjustments | 1 | 2 | 3 | |
| Adjusted Earnings Per Share | 0.6 | 1.4 | 1.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 38% | 0% | 0% | 0% |
| Operating Profit CAGR | 50% | 0% | 0% | 0% |
| PAT CAGR | 50% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -45% | NA% | NA% | NA% |
| ROE Average | 10% | 9% | 9% | 9% |
| ROCE Average | 11% | 8% | 8% | 8% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 13 | 28 | 31 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 18 | 17 | 26 |
| Other Non-Current Liabilities | -0 | 0 | 0 |
| Total Current Liabilities | 31 | 36 | 53 |
| Total Liabilities | 63 | 81 | 110 |
| Fixed Assets | 1 | 1 | 1 |
| Other Non-Current Assets | 1 | 0 | 0 |
| Total Current Assets | 61 | 80 | 109 |
| Total Assets | 63 | 81 | 110 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -28 | -9 | -4 |
| Cash Flow from Investing Activities | -1 | 0 | -0 |
| Cash Flow from Financing Activities | 30 | 8 | 5 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 0.57 | 1.38 | 1.75 |
| CEPS(Rs) | 0.61 | 1.46 | 1.83 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 10.82 | 15.91 | 17.66 |
| Core EBITDA Margin(%) | 5.61 | 5.17 | 4.54 |
| EBIT Margin(%) | 6.3 | 5.16 | 5.04 |
| Pre Tax Margin(%) | 3.44 | 2.64 | 2.65 |
| PAT Margin (%) | 2.6 | 2.01 | 1.85 |
| Cash Profit Margin (%) | 2.77 | 2.1 | 1.92 |
| ROA(%) | 1.12 | 3.42 | 3.25 |
| ROE(%) | 5.24 | 11.85 | 10.47 |
| ROCE(%) | 3.16 | 10.22 | 11 |
| Receivable days | 295.76 | 79.75 | 79.66 |
| Inventory Days | 442.02 | 111.85 | 105.89 |
| Payable days | 102.92 | 27.14 | 34.13 |
| PER(x) | 0 | 31.9 | 13.21 |
| Price/Book(x) | 0 | 2.77 | 1.31 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.94 | 0.97 | 0.56 |
| EV/Core EBITDA(x) | 30.01 | 18.52 | 10.87 |
| Net Sales Growth(%) | 0 | 353.27 | 37.6 |
| EBIT Growth(%) | 0 | 270.98 | 34.55 |
| PAT Growth(%) | 0 | 250.51 | 26.32 |
| EPS Growth(%) | 0 | 144.35 | 26.53 |
| Debt/Equity(x) | 3.03 | 1.47 | 1.72 |
| Current Ratio(x) | 1.96 | 2.24 | 2.07 |
| Quick Ratio(x) | 0.91 | 1.06 | 1.02 |
| Interest Cover(x) | 2.21 | 2.05 | 2.11 |
| Total Debt/Mcap(x) | 0 | 0.53 | 1.31 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Promoter | 56.72 | 56.72 | 56.72 | 56.72 | 56.72 | 56.72 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 43.28 | 43.28 | 43.28 | 43.28 | 43.28 | 43.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Promoter | 1 | 1 | 1 | 1 | 1 | 1 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
